Cameron Santoro

Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology (AAD) meeting. | Image […]

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Steven Daniel Daveluy, MD, FAAD, associate professor, program director, and clinical educator at Wayne State University, emphasizes the importance

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. At the American Academy of Dermatology 2025 annual conference, Shawn Kwatra, MD, FAAD, physician scientist at the University of

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, discussed the significant potential of teledermatology to enhance health care equity,

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut, discussed the promise of combination therapy to treat pediatric

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Lawrence F. Eichenfield, MD, FAAD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital and professor of dermatology

This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology. Rebecca Vasquez, MD, FAAD, associate professor in the department of dermatology at the University of Texas Southwestern Medical Center

Strict changes to immigration policies nationwide create a public health crisis in overcrowded detention centers, draining taxpayer dollars and diminishing undocumented immigrants’ contributions to subsidies. | Image Credit: Brad – stock.adobe.com The Trump administration’s stringent immigration policies are causing a

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. | Image Credit: wladimir1804 – stock.adobe.com Stoboclo and Osenvelt (both denosumab-bmwo), biosimilars to Prolia and Xgeva

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Seemal R. Desai, MD, FAAD, president of the American Academy of Dermatology (AAD), stated he is most looking